Gastric cancer: Clinical Practice Guidelines in oncology™

Jaffer Ajani, Tanios Bekaii-Saab, Thomas A. D'Amico, Charles Fuchs, Michael K. Gibson, Melvyn Goldberg, James A. Hayman, David H. Ilson, Milind Javle, Scott Kelley, Robert C. Kurtz, Gershon Yehuda Locker, Neal J. Meropol, Bruce D. Minsky, Mark B. Orringer, Raymond U. Osarogiagbon, James A. Posey, Jack Roth, Aaron R. Sasson, Stephen G. SwisherDouglas E. Wood, Yun Yen

研究成果: 雜誌貢獻文章同行評審

24 引文 斯高帕斯(Scopus)


Gastric cancer is rampant in several countries worldwide. Its incidence in the Western hemisphere has been declining for more than 40 years; however, the location of gastric cancer has shifted proximally in the past 15 years. The reason for this shift is unclear. Diffuse histology is also more common now than intestinal type of histology. Advances have been made in staging procedures, such as laparoscopy and endoscopic ultrasonography, and in possible functional imaging techniques. The current TNM classification requires an examination of at least 15 lymph nodes; a DO dissection is unacceptable. Patients with locoregional gastric carcinoma should also be referred to high-volume treatment centers. Combination chemotherapy and radiotherapy in the adjuvant setting for a select group of patients is the new standard in the United States. These guidelines provide a uniform systematic approach to gastric cancer in the United States. Investigation results for new chemotherapeutic agents, including antireceptor agents, vaccines, gene therapy, and antiangiogenic agents, and many future advances in the treatment of gastric carcinoma are anticipated.
頁(從 - 到)350-366
期刊JNCCN Journal of the National Comprehensive Cancer Network
出版狀態已發佈 - 4月 2006

ASJC Scopus subject areas

  • 腫瘤科


深入研究「Gastric cancer: Clinical Practice Guidelines in oncology™」主題。共同形成了獨特的指紋。